Sangamo publishes TRAC locus modular integrase retargeting presentation

Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

SGMO

0.00
  • Sangamo published a medical research presentation outlining a platform to retarget large serine integrases for targeted gene integration at therapeutically relevant genomic sites.
  • Work described retargeting Bxb1 integrase to TRAC locus, reaching about 29% targeted integration with up to 44% GFP expression in primary human T cells.
  • Zinc finger fusions lifted on-target performance while maintaining a stronger specificity profile than activity-boosting mutations, which reduced specificity in genome-wide off-target assays.
  • Synthetic donor engineering designed to remove need for wild-type Bxb1, with donor changes reported to eliminate top nominated off-target integration sites in K562 cells for most active TRAC reagents.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.